For over 100 years, Brigham and Women’s Hospital has provided world-class, compassionate cancer care to patients from all corners of the world. Our roots are deeply entwined in groundbreaking biomedical research. We’re proud to provide a comprehensive range of care within one of the nation’s highest-ranked hospitals. Our highly trained cancer specialists are at the forefront of surgical cancer care. We also provide premier radiation oncology therapy and outstanding diagnostic capabilities from the Brigham’s internationally renowned radiology and pathology departments.
At a time when more people are being diagnosed with cancer and other complex illnesses than ever before, Brigham and Women’s Hospital remains steadfast in our unwavering commitment to compassionately provide the advanced, research-infused care that will help define the future of the prevention, treatment and cure of cancer. Our focus, above all, is on delivering the highest quality of care to our patients.
In light of recent news from the Dana-Farber Cancer Institute, which we currently collaborate with to provide medical oncology services to our patients with cancer, we are providing additional information to our patients and their families in this question-and-answer section. Please don’t hesitate to also contact Patient and Family Relations at 617-732-6636 with any questions or concerns regarding your treatment and care.
No, there will be no changes to your care at this time or expected in the near future. At Brigham and Women’s Hospital, we have an existing agreement with Dana-Farber to provide collaborative cancer care through 2028.
The inpatient facilities and clinical collaborations that are in place today provide excellent patient care and outcomes. At the Brigham, we intend to continue to work with our colleagues at Dana-Farber over the next five years to provide an exceptional patient experience and plan thoughtfully for a future transition.
Yes. At the Brigham and across the Mass General Brigham health care system, we are committed to providing the very best care to patients with cancer. While our clinical collaboration with Dana-Farber may come to a close in 2028, our work to provide compassionate and specialized care to patients with cancer will continue. We will always be committed to our patients, and we will provide the full spectrum of integrated cancer care that you would expect from a nationally top-ranked hospital.
Until 2028, we expect that patients will continue to receive care at the current Dana-Farber and Brigham and Women’s Hospital campuses.
The Brigham and MGB are among the largest recipients of federal funding for cancer research, and we expect to continue to be a leader in this area beyond the transition and into the future. In addition to our own robust research programs, Brigham and Women’s Hospital is a participant in the Dana-Farber/Harvard Cancer Center (DF/HCC) research consortium. The DF/HCC is made up of more than 1,1,00 cancer researchers in Boston who collaborate on innovative research programs that help change the course of care for patients with cancer.
We are proud of the care we provide to our patients and look forward to continuing to care for you and your families for years to come.
For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.
About BWH
